G Bartzokis1, J Cummings, S Perlman, D B Hance, J Mintz. 1. Department of Psychiatry, University of Arkansas for Medical Sciences, Central Arkansas Veterans Healthcare System, Little Rock 72114, USA. gbar@ucla.edu
Abstract
OBJECTIVE: To quantify in vivo brain ferritin iron levels in patients with Huntington disease (HD) and normal control subjects. DESIGN AND SUBJECTS: A magnetic resonance imaging method that can quantify ferritin iron levels with specificity in vivo was employed to study 11 patients with HD and a matched group of 27 normal controls. Three basal ganglia structures (caudate, putamen, and globus pallidus) and 1 comparison region (frontal lobe white matter) were evaluated. RESULTS: Basal ganglia iron levels were significantly increased (P<.002) in patients with HD, and this increase occurred early in the disease process. This was not a generalized phenomenon, as white matter iron levels were lower in patients with HD. CONCLUSIONS: The data suggest that increased iron levels may be related to the pattern of neurotoxicity observed in HD. Reducing the oxidative stress associated with increased iron levels may offer novel ways to delay the rate of progression and possibly defer the onset of HD.
OBJECTIVE: To quantify in vivo brain ferritin iron levels in patients with Huntington disease (HD) and normal control subjects. DESIGN AND SUBJECTS: A magnetic resonance imaging method that can quantify ferritin iron levels with specificity in vivo was employed to study 11 patients with HD and a matched group of 27 normal controls. Three basal ganglia structures (caudate, putamen, and globus pallidus) and 1 comparison region (frontal lobe white matter) were evaluated. RESULTS: Basal ganglia iron levels were significantly increased (P<.002) in patients with HD, and this increase occurred early in the disease process. This was not a generalized phenomenon, as white matter iron levels were lower in patients with HD. CONCLUSIONS: The data suggest that increased iron levels may be related to the pattern of neurotoxicity observed in HD. Reducing the oxidative stress associated with increased iron levels may offer novel ways to delay the rate of progression and possibly defer the onset of HD.
Authors: J M G van Bergen; J Hua; P G Unschuld; I A L Lim; C K Jones; R L Margolis; C A Ross; P C M van Zijl; X Li Journal: AJNR Am J Neuroradiol Date: 2015-12-17 Impact factor: 3.825
Authors: Bart Larsen; Josiane Bourque; Tyler M Moore; Azeez Adebimpe; Monica E Calkins; Mark A Elliott; Ruben C Gur; Raquel E Gur; Paul J Moberg; David R Roalf; Kosha Ruparel; Bruce I Turetsky; Simon N Vandekar; Daniel H Wolf; Russell T Shinohara; Theodore D Satterthwaite Journal: J Neurosci Date: 2020-01-27 Impact factor: 6.167
Authors: Shafik N Wassef; John Wemmie; Casey P Johnson; Hans Johnson; Jane S Paulsen; Jeffrey D Long; Vincent A Magnotta Journal: Mov Disord Date: 2015-03-29 Impact factor: 10.338
Authors: Caroline K Jurgens; Radu Jasinschi; Ahmet Ekin; Marie-Noëlle W Witjes-Ané; Huub Middelkoop; Jeroen van der Grond; Raymund A C Roos Journal: PLoS Curr Date: 2010-09-08